Key terms
About JSPR
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in enabling cures through hematopoietic stem cell therapy. It focuses on the development and commercialization of safer, stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The company was founded by Judith Shizuru and Susan Prohaska in March 2018 and is headquartered in Redwood City, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JSPR news
Apr 03
6:49am ET
Jasper Therapeutics initiated with an Outperform at Evercore ISI
Apr 03
6:40am ET
Jasper Therapeutics initiated with an Outperform at Evercore ISI
Mar 27
4:25pm ET
Jasper Therapeutics initiated with an Outperform at RBC Capital
Mar 21
10:46am ET
Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
Mar 20
9:05am ET
Buy Rating Affirmed for Jasper Therapeutics as Briquilimab Shows Market Potential in Chronic Urticaria Treatment
Mar 20
9:00am ET
Analysts’ Top Healthcare Picks: Jasper Therapeutics (JSPR), Alphatec Holdings (ATEC)
Mar 19
8:03am ET
Jasper announces first patient dosed in Phase 1b/2a SPOTLIGHT study
Mar 18
5:45am ET
Buy Rating for Jasper Therapeutics: Promising Prospects for Briquilimab in Treating Chronic Urticaria
Mar 18
5:42am ET
Jasper Therapeutics initiated with an Outperform at TD Cowen
Mar 15
8:19am ET
Jasper Therapeutics presents Phase 1b/2a data on briquilimab
Mar 07
7:41am ET
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biomea Fusion (BMEA) and Jasper Therapeutics (JSPR)
Mar 07
1:02am ET
Bad News for Jasper Therapeutics, Inc. Stock: This New Risk Has Been Added
Mar 04
1:15pm ET
Buy Rating Affirmed: Jasper Therapeutics’ Progress and Potential in Addressing Unmet Needs in Chronic Urticaria Treatment
Mar 04
7:31am ET
Jasper Therapeutics reports Q4 EPS ($1.50), consensus ($1.61)
Feb 27
7:48am ET
Oppenheimer Reaffirms Their Buy Rating on Jasper Therapeutics (JSPR)
Feb 26
2:25pm ET
Buy Rating on Jasper Therapeutics Highlighting Briquilimab’s Potential in Chronic Urticaria Treatment
Feb 23
8:02am ET
Jasper Therapeutics presents data from preclinical briquilimab studies
Feb 21
9:45am ET
Buy Rating for Jasper Therapeutics: Promising Developments in CSU Treatment Pipeline and Anticipated Clinical Milestones
Feb 12
3:53pm ET
Fly Insider: Jasper, AMD among week’s notable insider trades
Feb 07
4:23am ET
Jasper Therapeutics Announces Offering Pricing Details
Feb 07
4:23am ET
Jasper Therapeutics Launches $50M Share Offering
Feb 06
9:02am ET
Jasper prices 3.9M shares at $12.95 per share in underwritten offering
Feb 06
7:16am ET
Oppenheimer Says There’s Room for up to 518% Gains in These 3 Under-the-Radar Stocks
Feb 02
8:02am ET
Jasper Therapeutics reports inducement grants under Nasdaq listing rule
Jan 17
10:18am ET
Jasper Therapeutics trading resumes
Jan 17
10:13am ET
Jasper Therapeutics trading halted, volatility trading pause
Jan 05
8:36am ET
Jasper Therapeutics announces key upcoming milestones
No recent press releases are available for JSPR
JSPR Financials
Key terms
Ad Feedback
JSPR Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
JSPR Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range